IDEAYA Biosciences Inc Stock News

IDEAYA Biosciences, Inc. (NASDAQ:IDYA ) 10-Year Anniversary R&D Day Conference Call Company Participants Yujiro Hata - Founder, President, CEO & Director Arun D. Singh - Director of Ophthalmic Oncology, Cleveland Clinic Darrin M.

I am upgrading IDEAYA Biosciences to a "Strong Buy" due to multiple positive clinical updates and robust pipeline progress. Darovasertib showed strong interim phase 2 data in neoadjuvant uveal melanoma, achieving tumor shrinkage, reduced radiation, and improved vision. IDE849 demonstrated high objective response rates in SCLC and NECs, with expansion potential into other solid tumors and combin...

Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodelvy® (Dose level 2); ORR of 33% (3/9; 3cPR) at 15 mg IDE397 plus 10mg/kg Trodelvy® (Dose level 1) Manageable safety profile at both expansion doses, consistent with known adverse events observed with each agent alone, with no treatment related serious adverse events obse...

Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in the neoadjuvant setting of primary uveal melanoma Manageable safety profile with mostly Grade 1 and 2 treatment-related adverse events Phase 3 registration-enabling OptimUM-10 trial of darovasertib i...

80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE849 77.1% (27/35) ORR and 60.0% (21/35) confirmed ORR (4 pending confirmation) in 2L SCLC; a 73.2% (52/71) ORR and 47.9% (34/71) confirmed ORR (10 pending confirmation) were observed ...

SOUTH SAN FRANCISCO, Calif. , Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2a) inhibitor, and Trodelvy® (...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA ) Cantor Global Healthcare Conference 2025 September 3, 2025 9:10 AM EDT Company Participants Yujiro Hata - Founder, President, CEO & Director Joshua Bleharski - Chief Financial Officer Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Good morning, everyone. Welcome to the ...

Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A inhibitor, will be presented at the 10-Year Anniversary R&D Day on September 8 th SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision...